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Abstract
The human leukocyte antigen (HLA) system or complex plays an essential role in regulating the immune system in humans. Accurate prediction of peptide binding with HLA can
efficiently help to identify those neoantigens, which potentially make a big difference in immune drug development. HLA is one of the most polymorphic genetic systems in humans, and
thousands of HLA allelic versions exist[6]. Due to the high polymorphism of HLA complex,
it is still pretty difficult to accurately predict the binding affinity. In this thesis, we presented a
new algorithm to combine convolutional neural network and long short-term memory to solve
this problem. Compared with other current popular algorithms, our model achieved the stateof-the-art results.

Keywords: Bioinformatics, deep learning, health informatics, machine learning, HLA
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Summary for Lay Audience
In recent years, deep learning has witnessed many significant breakthroughs in different
areas and achieves encouraging results. Various machine learning methods have also been
applied in bioinformatics fields. Due to the importance of major histocompatibility complex
(MHC) in immunity, many models have been developed for MHC-peptide binding prediction.
However, it is still difficult to accurately predict the MHC-peptide binding specification for all
the MHC alleles now.
In this thesis, we proposed a novel model which combined convolutional neural network
and long short-term memory to solve this problem. Our model has been tested with the experimental benchmark from IEDB and shows powerful performance compared with other currently
popular algorithms.
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Chapter 1
Introduction
In this chapter, we introduce the background of major histocompatibility complex, especially
its function in immunology, the importance of the research question, and our contribution to
solve it. The thesis layout is illustrated at the end of this chapter.

1.1

Biological Background

The major histocompatibility complex (MHC) proteins are critical for the adaptive immune
system recognizing foreign molecules in most mammalian species. MHC are the chaperones
for endogenous peptides which are transferred to the cell surface through binding with MHC
(the MHC-peptide complex) as the antigens for T cell recognition. Essentially, T cells would
tolerate the auto-antigens, but activate when the allo-antigens appear [38]. Those MHC proteins are called human leukocyte antigen (HLA) complex in human beings, and they help our
immune system to distinguish pathogens (foreign molecules) through binding to peptide antigens and exposing them to the surface of cells for recognition by certain T cells. Research
on the canonical mechanism of MHC-peptide binding can benefit our comprehension of which
peptides bind to MHC (potentially resulting in an immune response). This could be in favor for
cancer treatments. Specifically regarding the mutated or tumor cells, some peptides originates
from altered tumor proteins and they are known as neoantigens. Those neoantigens would
1
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be the ideal antigens for the development of protein-based vaccines and drugs to treat tumor
patients[22]. Recent advances in cancer immunotherapy have confirmed this new treatment
boosts T cell activity to destroy cancer cells in both mouse models and human patients[20].

Figure 1.1: MHC Class I Processing.[38]: Proteins are degraded into peptides by the proteasome. peptides convey into the endoplasmic reticulum, where they combined with MHC-I
molecules. MHC-I/peptide complexes enter Golgi apparatus, are glycosylated, enter secretory
vesicles, fuse with the cell membrane, and externalize on the cell membrane interacting with T
lymphocytes
MHC can be further divided into three subgroups: MHC class I, MHC class II, and MHC
class III. Among those, MHC class I and MHC class II attract more research attention due
to they directly involve in antigen presentation of immunology[14]. Class I MHC binds to
peptides from intracellular proteins, while class II MHC binds to extracellular peptides that
are brought inside the cell. Figure 1.1 illustrates the MHC class I pathway. MHC class I
plays an irreplaceable role in cell-mediated immunity, which could resolve in intracellular
pathogens such as viruses and some bacteria. MHC class I mediates the destruction of infected
or malignant host cells (cellular immunity) by interacting with CD8 molecules on surfaces of
cytotoxic T cells. In human beings, the MHC complex is also called the human leukocyte
antigen (HLA) system. There are three class I in humans: HLA-A, HLA-B and HLA-C.

1.1. Biological Background
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As shown in Figure 1.2, MHC class I molecules are heterodimers, which are made up of
two polypeptide chains - α and β 2 -microglobulin (b2m) and the two chains are linked through
the interaction between b2m and the α3 domain[38]. Regarding those chains, the α chains
are polymorphic and encoded by MHC genes, while the b2m subunit is not polymorphic and
encoded by the β 2 -microglobulin gene[38]. The α3 domain is plasma membrane-spanning
and interacts with the CD8 co-receptor of T-cells. The α3-CD8 interaction holds the MHC I
molecule in place while the T cell receptor (TCR) on the surface of the cytotoxic T cell binds
its α1-α2 heterodimer ligand, and checks the coupled peptide for antigenicity[38]. The α1
and α2 heavy chain domains fold to form the active binding pocket for short antigenic peptide
peptides to bind, and the peptides binding to MHC class I molecules are mostly in 8-10 amino
acid in length[5]. Those α1, α2, and α3 domains create a globular protein in which a β-pleated
sheet forms the floor of the peptide-binding groove and is bounded by two helical regions that
form the sides of the groove[8].

Figure 1.2: The structure of MHC class I molecules.[38]

4
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Research Question

In this thesis, we concentrate on predicting peptide binding to MHC/HLA through deep learning methods. In particular, we try to solve peptide-MHC binding prediction problems by using
Recurrent Neural Network and VGG-based Convolutional Neural Network, and then compare
our model performance with other currently popular models.

1.3

Difficulty

Accurate prediction of peptides binding to MHC still faces a big challenge. The difficulty
could refer to two unique properties of MHC: Polygenes and polymorphism. Polygenes mean
each individual possesses several different MHC genes, which results in diverse range of
peptide-binding specificities. The polymorphism of MHC stands for that the organism differs diversely from each other within the same species[14]. Many different alleles exist inside
a population[38]. The MHC genes are the most polymorphic genes, as we know so far. The
polymorphism is so high, no two individuals have exactly the same set of MHC molecules except for the twins[38]. Those properties lead to experimental characterization for peptide-MHC
binding costly and time-consuming. Therefore, in silico computational approaches have been
proposed to study this research topic, especially when large amounts of in vitro binding affinities data are available in public databases like the Immune Epitope Database (IEDB)[9, 32].
Although there are over a half million of experimentally characterized binding affinities data
in the IEDB database, they are not evenly distributed across the alleles. The experimental data
could be as many as 10000 characterized peptide-MHC binding affinities for common alleles,
while it may be as few as 100 for other rare alleles. Besides, most peptides in MHC class
I ligands data represented as 9 amino acids (aa) in length, but it also varied critically among
MHC alleles. For example, the H-2Kb allele has a preference for 8 aa-long peptides, while
HLA-A*01:01 has nearly one-third of MHC-presented peptides which have a length of 9 aa.

1.4. Machine Learning in MHC-binding Problem
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Figure 1.3: Polymorphism and Polygeny of MHC molecules. Taken from the source:
Immunobiology, Garland Science[13]. Picture 1.3a(polymorphism) shows the expression of
MHC alleles is codominant and most individuals are likely to be heterozygous at each locus.
Therefore, two combinantions (shows as the colors) can be found as the result. Picture1.3b
indicates the polygene where three genes could leads to 3 combination. Picture 3c (Polymorphism and Polygeny) represents that after combining polymorphism and polygenes, it could
lead to 6 different combinantions.

1.4

Machine Learning in MHC-binding Problem

In recent years, various machine learning methods have been applied in bioinformatics fields.
Figure 3.3 indicated the general process of deep learning in bioinformatics. Inside those methods, due to the importance of MHC in immunity, many models have been developed for MHCpeptide binding prediction to either predict the binding affinity (a regression problem) or to
predict whether a peptide could bind to the MHC allele (a classification problem)[3]. Among
all of the models, studies on predicting peptide binding to HLA class I molecules have been
more active due to the availability of the large-scale high-quality peptide-HLA binding data as
provided by IEDB database, and the automated benchmark platform for comparing, tracking,
and scoring the progress of several current popular online computational methods[34]. There
are mainly three categories of models for HLA-peptide binding prediction: allele-specific, consensus, and pan-specific models[27, 29, 53, 11].
Most of these models make full use of machine learning algorithms, such as artificial neu-

6
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Figure 1.4: Application of deep learning in bioinformatics. taken from the source: Deep
learning in bioinformatics, Min et al. [24]
ral networks (ANN), Convolutional Neural Networks (CNN), and Recurrent Neural Networks
(RNN), to extract the motifs features. Machine learning algorithms can build complex nonlinear models to achieve outstanding prediction performance in the HLA-peptides binding affinity
prediction[51].

1.5

Contributions

In this thesis, we propose a new model to solve HLA-peptide binding prediction problems.
Our model is developed based on pan-specific models and combines the strengths of CNN and
RNN architectures. Compared with other currently popular models, including NetMHCPan3.0,
NetMHCPan4.0, PickPocket, SMM, NetMHC3.4, NetMHC4.0, ARB, MHCflurry, AMMPMBEC, IEDB Consensus and netMHCcons, our model achieved state-of-the-art results on various HLA alleles with excellent generalization performance.
The main contribution of this thesis is as follows:
• We proposed a well-performed binding probability prediction model called MHCherryPan, which achieved the state-of-the-art results on a large number of HLA alleles.
• The novel design which combines CNN-based and RNN-based extractors in one panspecific model enables our model to deal with any length peptide sequences and also
have good generalization capability.

1.6. The Structure of this Thesis
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• Our model takes raw sequential data as input, which could be potentially used in any
RNA-protein, DNA-protein, and RNA-DNA binding prediction.

1.6

The Structure of this Thesis

The rest of the thesis is organized as follows. In Section 2, we provide an overview of the
related work. In Section 3, we describe our new approach - MHCherryPan for predicting
HLA-peptide binding. In Section 4, we discuss the experiment setup, including the datasets
that we use and some experiment details. In Section 5, we compare our new model with other
popular models. Section 6 concludes this paper.

Chapter 2
Machine learning and related works
In this section, we first introduce the frequently-used machine learning algorithms in the bindingprediction problems and then we would focus on the previous work done for HLA-peptide
binding prediction, which can be classified into allele-specific, pan-specific, and consensus
models. In the end, we will summary the related works and introduce our model.

2.1

Machine learning algorithms on binding predictions

Currently, the neural network is the dominant machine-learning algorithm for peptide-binding
prediction problems [23]. Among different fundamental architectures of neural networks for
binding prediction algorithms, Artificial Neural Networks, Convolutional Neural Networks and
Recurrent Neural Networks are the most popular deep learning methods which have all been
applied and achieved inspiring results.

2.1.1

Artificial Neural Networks

Deep learning, as a member of the broader family of machine learning methods, is based on
artificial neural networks with representation learning [44]. The reason why it is so-called is
due to the learning complexity. Generally speaking, deep learning model contains much deeper
8
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layers such as two or more hidden layers whereas shadow learning usually only contain one
layer. Deep learning have been applied to fields such as speech recognition, computer vision,
natural language processing, audio recognition, social network filtering, machine translation,
bioinformatics, drug design, medical image analysis, material inspection and board game programs, where they have produced inspiring results which could be comparable or surpassing
human performance[44].
Artificial Neural Network is an information processing model acquire, store and utilize
experimental knowledge and it is is inspired by the way biological nervous systems, such as the
brain, process information[55] . Artificial Neural Networks (ANN), as one of the most popular
deep learning algorithms, have been successfully applied on several significant bioinformatic
topics such as DNA-binding and RNA-binding prediction as well as HLA-peptides binding
predictions[1]. An ANN is usually consisted of neurons that are connected to each other, and
ANN has three general types of layers: the input layer, the hidden layer, and the output layer,
as shown in figure 2.1. The input layer brings the initial data such as variables or features of
a given problem into the system for further processing by subsequent layers. These inputs are
then propagated through the hidden layers to the output layer. The hidden layers perform a
series of (non)linear functions that convert the input data into data that the output layer can
use. This conversion is often called feature extraction since the network learns which input
data is more important than others.
ANN can capture the complex inter-relationships in the non-linearity among data variables
and has been used in classification and recognition tasks as well as motifs feature extraction[51].
Most of the ANN-based prediction models on HLA-peptides binding affinity prediction, such
as netMHC [21], and MHCflurry[28], only include one or two full-connected layers, with
the optimizing network structures and parameters for different MHC alleles. Although ANNbased approaches are remarkable for its accuracy, they lose flexibility due to they limit the
input length of peptide epitopes (8-15 amino acids for MHCflurry) and support only specific
MHC alleles that the models have been trained for[16].

10
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Figure 2.1: Artificial Neural Networks[41]

2.1.2

Feedforward Neural Network and Convolutional Neural Networks

A feedforward neural network is an artificial neural network in which connections between the
nodes do not form a cycle[52]. As the name indicates, it is a network where the information
flows in one single direction. Information spreads from one layer to the next, starting at the
input nodes, through the hidden nodes, and ending in the output nodes. A non-linear so-called
activation function, most often tanh or sigmoid, is applied to give the output of a neuron given
its input. Figure 2.2A indicated the architecture of the feedforward neural network. The hidden
layer of a feedforward neural network is also referred to as a dense layer because it is fully
connected to the previous layer.
Convolutional Neural Networks (CNNs) are a type of deep feedforward neural network.
The name ”convolutional Neural Networks” is due to that the network utilized a mathematical
operation called convolution, which is a specialized kind of linear operation [43] as shown
in Figure 2.2b. Convolutional networks are neural networks that use convolution instead of
the general matrix multiplication in at least one of their layers[43]. CNNs usually consist of

2.1. Machine learning algorithms on binding predictions
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Figure 2.2: The illustration of Feed Forward Neural Network and Convolutional Neural
Network. Reproduced from original paper[16]: (A) Feed forward network. (B) Convolutional neural network. (C) A filter can be visualized as a sequence motif.
multiple convolutional layers with many convolutional filters and pooling layers (the function
is to downsample an input representation), which makes the model able to learn many highly
abstract features[18]. CNN have achieved amazing result in some fields especially in image
classification. In the field of HLA binding, the HLA-CNN[35] , which uses three convolutional
layers and two fully- connected layers with word embedding for encoding, achieves good performance and outperforms all traditional prediction methods. DeepSepPan[19] utilized the
VGG-liked deep CNN to extract abstract features from HLA. Although it also achieves competitive performance compared with other current algorithms, DeepSeqPan loses flexibility and
only supports the peptides which have 9 aa length.

2.1.3

Recurrent Neural Networks

A Recurrent Neural Network (RNN), as shown in figure 2.3, is a special type of neural network
because (unlike feedforward neural networks) it contains directed cycles. RNN layers use the

12

Chapter 2. Machine learning and related works

Figure 2.3: Basic recurrent neural network[41]
output of the network at a certain iteration as input for a next iteration. This recursive aspect of
RNN make them extremely useful for sequential data, especially if the output of the network
for a certain element depends on both that element and the output of the previous element(s).
RNN has been used to encode time-series information in many tasks due to that RNN can
better capture temporal relationships by remembering previous inputs[16]. A popular choice
for RNN is the Long Short-Term Memory (LSTM), which alleviates the vanishing and exploding gradient problems presented in normal RNN[16]. MHCpred[10] with the structure of
deep RNN, which applies three LSTM layers and adaptively learns the appropriate parameters
to enable the model to learn the hidden features more efficiently. Another big merit of RNN
is that there is no limit for the peptide length due to RNN utilizes the masking layers, so it
doesn’t require fixed-length inputs. In this case, those RNN-based prediction models could be
very flexible in the input length.

2.2

Models on HLA-peptide binding prediction

In order to accurately predict peptides binding MHC and identify ideal neoanitgen for proteinbased vaccine development, many models have been developed during the last several years.
There are different ways to classify those models. For example, based on the result the model
generates, they could be divided into regression model (predicting binding affinity) or clas-
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sification models(predicting binding or not). If we focus more on the algorithms or model
themselves, most of the models for HLA-peptide binding prediction can be divided into three
categories: allele-specific, consensus, and pan-specific models[27, 29, 53, 11].

2.2.1

Allele-specific Models

Allele-specific models have been proposed to predict the specificity of one receptor (one HLA
Allele) based on training data regarding this one HLA allele. In allele-specific models, each
HLA allele would have a separate allele-specific prediction model. MHCflurry is a recent proposed allele-specific model that achieved state-of-the-art results compared with other algorithms[28].
MHCflurry
MHCflurry, as one of the most well-performed allele-specific model, is developed using
separate artificial neural networks (ANNs) for each supporting allele, which consists of locally
connected layers and a fully connected layer [28]. As mentioned previously that allele model
need to have separate prediction model for each allele, MHCflurry designed an ensemble of
8-16 neural networks for each supported MHC allele trained on affinity measurements from
IEDB and other sources[28].
Figure 2.4 indicates the flow chart for the MHCflurry model. As the figure 2.4 shows, peptide data sequences are firstly padding into 15 amino acids by adding a ‘no-residue’ character
(‘X’). The reason why they padding through the mid of the peptide sequences instead of regular
padding method (padding to the beginning or the end) is to maintain the position of the anchor
residue (please also see in section 3.4 prepossessing). After padding, the peptide sequence
is then encoded into a tensor with dimension size of 15 x 21 by using BLOSUM 62 matrix.
Regarding the activation function for the model, MHCflurry uses the hyperbolic tangent function for the hidden layers and the sigmoid function for the final output layers. MHCflurry
had separate networks trained for each supported MHC allele, and each network contains the
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locally-connected layers, fully-connected layers and an affinity predictor.

Figure 2.4: MHCflurry Flow Network. Reproduced from original paper [28]: Neural
network architecture
NetMHC 4.0
NetMHC 4.0 is another popular allele-specific model, which is also developed using artificial neural networks (ANNs). NetMHC 4.0 develops an ensemble method to generate the
feed-forward networks and assigns the binding core of a given peptide based on the majority vote of the networks in the ensemble [2]. NetMHC 4.0 uses both sparse encoding matrix
(a matrix in which most of the elements are zero such as one-hot key) and BLOSUM62 (see
explanation in 3.2.2) to encode the peptide sequences into nine amino acid-binding cores.
But unlike MHCflurry padding all peptide sequence into 15 amino acids, NetMHC 4.0
developed a novel deletion-and- insertion methods, which is used to reconcile peptide sequence
into a core of nine amino acids. As figure 2.5 shows the example of insertion and deletion for
peptide. Regarding the peptide which the sequence length is 8 or 10, the NetMHC would first
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reconcile into the 9-amino acid peptides by inserting or deleting at all possible positions, which
results in multiple potential sequences. After that, it will select the highest predicted score with
the current configuration of the neural network is taken as the optimal binding core[2] . In
addition, NetMHC does not public their detailed implementation and code.

Figure 2.5: The example of insertion and deletion for peptide. Reproduced from original
paper [2]: Left(a) is the insertion example for peptide ”AILDFTHL” and the right(b) is the
deletion example for peptide ”FYGERPLTRY”

2.2.2

Pan-specific Models

Although those allele-specific models usually have high excellent performance on some common HLA alleles which have large amounts of experimental data but predict poorly on other
alleles with few experimental data. This will cause a big issue since many alleles only have
a few experimental data available. Therefore, researchers proposed the pan-specific models to
solve this data scarcity issue.
The main idea of the pan-specific model is to use the data from all the alleles of HLA
for model training so that it could predict the binding results of the HLA alleles, which may
have less experimental data or do not appear at all. The pan-specific model would encode both
the peptides and the HLA alleles protein as inputs. The peptide-HLA binding environment is
represented in this way so the deep learning models can be trained on all peptide-HLA binding
data[54].
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NetMHCPan

Figure 2.6: Interaction map of the HLA pseudo sequence in NetMHCPan. Reproduced
from original paper[19]
NetMHCPan is the first pan-specific MHC-peptide binding prediction algorithm and it
achieves state-of-the-art result in prediction performance [27]. One of the significant contributions of NetMHCPan is that they designed a novel pseudo sequence to stand for the HLA
binding motifs. In their method, an HLA sequence is reduced to a pseudo amino acid sequence
of length 34, and each amino acid in this pseudo sequence is selected if it is in contact with the
peptide within 4.0 A [27].
The interaction map in Figure 2.6 is extracted based on a representative set of HLA structures with nonamer peptides, and this extracted 34-length pseudo sequence is a list of location
indexes of amino acids in the HLA sequence[27]. Therefore, NetMHCPan represents each
MHC sequence as a 34 corresponding residues, and an HLA-peptide binding sample is represented as a 43-length amino acid sequence (34 from the HLA and 9 from the peptide). The
input is then used to train multiple feedforward neural networks, and the network with the highest prediction performance on the evaluation set was selected as the final prediction model[27].
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PickPocket
PickPocket is another popular pan-specific model for predicting peptide-MHC binding.
The main idea of PickPocket is to use statistical approach to calculate the binding score for
each candidate peptide sequence. For each supported HLA alleles, amino acids that frequently
occur at anchor positions (the positions where certain amino acids appear more) given the
higher value. The less frequent amino acids are assigned with lower values [53]. The final
score of a sequence is the sum of values at each position.
PickPocket constructs position-specific scoring matrices (PSSMs) for each MHC alleles,
which are derived from peptide ligands in the training data. In order to support MHC alleles
with insufficient data, PickPocket developed a novel pocket-specific binding method. These
pockets are derived form specificity determining interactions with amino acid side chains distributed along the length of the ligand [53]. Therefore, pocket library could be built from MHC
alleles for where a significant amount of peptide-binding ligands data was available to construct a PSSM for those rare HLA alleles which have insufficient experimental data. In order
to calculate the similarity between the a rare MHC allele and the MHC allele with a calculated
PSSM from the training dataset, the similarity function is used as following:
S (sq , si )
S im(sq , si ) = p
S (sq , sq )S (si , si )

(2.1)

S(sq , si ) indicates the similarity score between the two pocket sequences Sq and Si.
By doing this, PickPocket could calculate a weighted average PSSM for those unknown or
rare MHC alleles based on pocket similarities of all calculated HLA PSSMs from the training
set. Figure 2.7 indicates the more-detailed flow network for PickPocket. PickPocket firstly
extracts the position-specific vectors from the PSSMs in association with pseudo-sequence to
construct a pocket library and each pocket library entry is characterized by nine pairs, where
each pair consists of a specificity vector and a list of pocket amino acids[53]. Each number
corresponds to the following steps: (1) Build up PSSMs from ligands data; (2) Extract pseudosequences for the pockets; (3) Extract the position-specific vectors to construct a pocket library;
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Figure 2.7: PickPocket Flow Network. Reproduced from original paper [53]
(4 and 5) Input a query MHC, the model retrieves the position-specific vectors and calculates
mean vectors (6) The algorithm constructs a virtual PSSM for the target allele[53].

2.2.3

Consensus Models

The third one is called the consensus model. Due to some models may predict well for one
given HLA molecule but perform poorly for others, a consensus model usually uses several
different models and produces a prediction result based on all of them, which is usually defined
as a simple average of those models[26]. The objective of consensus algorithms is to achieve
an optimal combination of a series of prediction methods[17] for any given HLA molecule in
an automatic manner[17]. There are some current popular consensus models, such as IEDB
Consensus and netMHC-cons.
NetMHCcons
NetMHCcons is a popular consensus model for peptide-MHC binding prediction. In particular, two ANN-based MHC-peptide prediction models (NetMHC 3.4 and NetMHCpan) and
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one PSSM-based model (Pickpocket 1.1) have been utilized in this approach. NetMHCcons
provides three options for peptide binding prediction to different MHC alleles. Each of the
included models was first benchmarked separately and performance evaluated prior to the application of the consensus method [17]. In the end, the output result of NetMHCcons model is
defined as following:






NetMHC pan + Pickpocket







NetMHCcons = 
NetMHC + NetMHC pan










NetMHC pan

if distance >= 0.1
if distance = 0

(2.2)

if 0 < distance < 0.1

where distance refers to the distance between the query HLA alleles and its nearest neighbour
in the reference HLA allele list

2.3

Our Novel Design

Model Name

Category

Year

Special Design

Algorithm

Last Update

NetMHC4.0
MHCflurry
NetMHCPan 4.0
PickPocket
NetMHCcons

Allele-specific
Allele-specific
Pan-specific
Pan-specific
Consensus

2014
2018
2017
2009
2012

Insertion and deletion
Padding
HLA pseudo code features
Pocket Library
Sequence-based features

ANNs
ANNs
ANNs
PSSM
Consensus

October 2017
January 2019
January 2018
January 2017
January 2017

Table 2.1: Summary of related works for predicting MHC-peptide ligands.
The online link to access the above mentioned models are as following:
NetMHC 4.0: http://www.cbs.dtu.dk/services/NetMHC/;
MHCflurry: https://github.com/openvax/mhcflurry/;
NetMHCPan-4.0, http://www.cbs.dtu.dk/services/NetMHCpan/;
PickPocket 1.1: http://www.cbs.dtu.dk/services/PickPocket/;
NetMHCcons-1.1; http://www.cbs.dtu.dk/services/NetMHCcons/;
Table 2.1 is a summary of the related works as we discussed previously. Those model
are still frequently used today and can be considered as the state of the art for peptide-MHC
binding prediction problems. Currently, most of the prediction models are based on single
machine learning algorithm, such as ANN-based, CNN-based and RNN-based model. But as
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explained in machine learning section, considering that CNNs are excellent in extracting motifs
features from protein sequence and RNN performs well on sequential data, in this thesis, we
propose a novel pan-specific model called MHCherryPan which makes full use of CNN and
RNN architectures to predict the binding affinity between HLA class I and peptides by using
large-scale public datasets. We compared our model with other current popular models, and
the result proved our model performed very well on the HLA-peptide binding problem and
achieved state-of-the-art results on a large number of HLA alleles with good generalization
capability.

Chapter 3
Methodology
In this chapter, we propose a new model called MHCherryPan to solve HLA-peptide binding prediction problems, and then we would elucidate our approach thoroughly. Firstly, we
demonstrate the problem that we want to solve, then we explain our model in detail, including
encoding the input data, extracting peptide features, extracting HLA features, and predicting
HLA-peptide binding affinity. Lastly, we would combine all the modules we discussed and
introduce the pipeline for our model, which would give a big clear picture.

3.1

Problem statement

In this thesis, we build up a deep learning model to predict peptide binding to MHC/HLA
through deep learning methods. In particular, we try to solve peptide-HLA binding prediction
problems by using Recurrent Neural Network and VGG-based Convolutional Neural Network
and then compare our model performance with other currently popular models.

3.2

Encoding

This section introduces the genetic codes for amino acids and how we transform them into the
numeric representation by using the encoding matrix.
21
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3.2.1

Genetic Codes for Amino Acids

The MHC/HLA and antigen peptides are composed of amino acids. There are around 500
amino acids known, but merely 20 amino acids appear in the genetic code[36]. Those 20
amino acids are used to represent the input data (peptides and HLA). Any one of these 20
amino acids has its name, but it also has the three-letter or one-letter representations which are
commonly used in literature including this thesis:
alanine - ala - A

lysine - lys - K

arginine - arg - R

methionine - met - M

asparagine - asn - N

phenylalanine - phe - F

aspartic acid - asp - D

proline - pro - P

cysteine - cys - C

serine - ser - S

glutamine - gln - Q

threonine - thr - T

glutamic acid - glu - E

tryptophan - trp - W

glycine - gly - G

tyrosine - tyr - Y

histidine - his - H

valine - val - V

isoleucine - ile - I

asparagine/aspartic acid - asx - B *

leucine - leu - L

glutamine/glutamic acid - glx - Z *

*The last two amino acids (B and Z) are special due to sometimes it is difficult or impossible
to differentiate between two amino acids. This uncertainty to identify between two amino acids
(asparagine and aspartic acid, glutamine and glutamic acid) is shown with a special symbol (B
or Z).

3.2.2

Encoding Method

When working with amino acids sequence data, the numeric representation of amino acids,
which also is called encoding, will affect the model performance. Currently, there are two
common encoding solutions for amino acids. The first is a simple method called a one-hot
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encoding model in which each amino acid is represented by a unit binary vector of length n,
containing a single one and (n-1) zeros, e.g. [1,0,0, ., 0] for one amino acid and [0,1,0, ., 0 ]
for another amino acid. The value of that channel is set to one if the corresponding amino acid
appears, and the rest channels remain zero. This solution fairly treats all amino acids.
Another one is to use the BLOSUM matrix for encoding, representing each amino acid
by its corresponding row in the BLOSUM matrix. The BLOSUM matrix is a substitution
matrix to score alignments between evolutionarily divergent protein sequences [12]. Instead of
fairly treating all amino acid, the BLOSUM matrix keeps the evolutionary information about
which pairs of amino acids are easily interchangeable during evolution(i.e., which amino acid
positions are highly variable and which are conserved)[16]. This will be very important in
peptide-protein binding prediction.
In our MHCherryPan model, every input is a pair match of an HLA and a peptide. Taking
the peptide and the HLA as the pair inputs, we utilize the Blosum62 matrix to encode according
to locations of amino acids in sequences. Figure 3.1 shows the BLOSUM62 Matrix. Each
peptide and HLA are represented to the network as a series of amino acids; each amino acid
is represented as a 21-dimensional, smoothed, and blosum62- encoded vector. The peptide
sequence is encoded into a tensor with the dimension as 1 × 15 × 21, where the last dimension
number represents the number of channels and every channel stands for one of 20 amino acids
and one extra for padding and masking. 15 represents the peptide length. Although we choose
15 as the maximum length for peptide, our model can accept any-length peptides due to that
we use the masking layer in RNN, which can handle variable-length inputs by skipping any
input with mask value by copying the previous hidden state of the cell.
We tested our model on alignment-ready HLA sequences with different lengths and chose
the length 180 as the fixed dimension. Then we encoded each aligned HLA sequence into a 2D
tensor with dimension 1 × 180 × 21. We acquired alignment-ready HLA - 2895 sequences of
length 180 amino acids from the IMGT/HLA database[30]. Therefore, we encode each aligned
HLA sequence into a 2D tensor with dimension 1 × 180 × 21 in our model.
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Figure 3.1: BLOSUM62 Matrix: The BLOSUM62 matrix is used to encode peptide and HLA
sequences.

3.3

Model

In this section, we explain our model in detail, including how to extract peptide features, how
to extract HLA feature, and how to predict HLA-peptide binding based on extracted peptide
features and HLA features.

3.3.1

Peptide Feature Extraction Module

Recurrent neural networks (RNN) are neural network models for sequential data, and they have
time-delayed connections between the neurons of a hidden layer. RNN process one element
of the sequence at a time. In biological sequence context, RNN process one residue after the
other[16]. The information, therefore, flows both from input to output and along the sequence.
In this way, memory is generated and the neural network gains the ability to store and integrate
information from past inputs. Long short-term memory (LSTM) neural networks are a particular type of RNN in which the scalar-valued hidden neuron is replaced with the LSTM memory

3.3. Model

25

Figure 3.2: Peptide Feature Extractor - RNN

block[16]. The LSTM memory block is inspired by a computer memory cell and is easier for
the network to store a given input over many time steps[16].
LSTM can take input sequences with varying length by using the masking layers, which
makes LSTM highly flexible for dealing with unfixed length sequential data. In our model,
LSTM was chosen as the extracting methods for peptide feature extraction in order to generalize the relationship between the amino acid representation in peptide sequence. Figure 3.2
shows the RNN peptide feature extractor. We used the Bi-direction LSTM layer with 128 number of units. Our peptide feature extraction section processes one amino acid from an entire
sequence of peptide at a time, then predict whether it has the certain biological property after
having seen the whole sequence. We utilized the bidirectional approach (biLSTM) where the
network processed the input sequence forwards and backwards. In this way, each prediction
was determined by not just what came before the current position but also what comes after.
Recurrent neural networks use the output of a certain element in the sequence as an extra
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Figure 3.3: HLA Feature Extractor - CNN
input when handling the next element of that sequence. This allows the network to learn
dependencies between elements of the same sequence. This is exactly the type of situation we
are in. We presume that sequential features, such as the order or (relative) position of certain
amino acids in the proteins sequence will influence the reaction between these proteins. This
is the type of dependencies we want to discover. For this reason, choosing a recurrent neural
network seems to be the more promising strategy for our problem.

3.3.2

HLA Feature Extraction Module

CNNs consist of several convolutional layers with many convolutional filters and maxpooling
layers. Maxpooling layers enable the network to become invariant to small local deformations
in the input[16]. In CNN, information flows only from the input to the output through layer by
layer. They are not fully connected, but use a filter (a set of weights) over the input and feed
the information into a different neuron in the next layer. The filter will thereby identify features
in input irrespectively of where they appear[16]. We utilized a convolutional filter to detect a
motif in an amino acid sequence.
Inspired by DeepSeqPan, we defined a similar Convolutional Block to extract high-level
features from raw sequence data. As Figure 3.3 indicates, our convolutional block (ConvBlock)
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consists of two blocks with convolutional, batch normalization (a technique for training very
deep neural networks that standardizes the inputs to a layer for each mini-batch), max pooling
and LeakyReLu layers (an activation function to transfer the negative number into a smaller
number). Unlike DeepSeqPan that has many parameters needed to train, We simplified the
structure and optimized it to extract the protein sequences data with 180 aa lengths. In our
model, we applied a VGG-liked network configuration to extract the high-order features. VGG
is a straight forward CNN architecture and the main idea is to stack the convolutional layers
with increasing filter sizes. Information stored inside HLA proteins can be learned by the
neural network automatically with its end-to-end training framework.

3.3.3

Affinity Prediction Module

As the training data is all labeled with the IC50 value (which is an experimental way to measure
the affinity value between two peptides, see section 4.4.4 for more details), we devised our
output layer to produce the predicted IC50 value for the input MHC/HLA - Peptide pair. To
predict whether the input MHC/HLA - Peptide pair binding or not, we used a thread-hold value
to get the binary label. We set the threshold value into 500nm, which is also commonly used by
most of currently popular models such as MHCFlurry, DeepSeqPan, NetMHCPan and so on.
The reason why most of the current models are using IC50 value as the label instead of using
the binary label (0 for not binding and 1 for binding) is due to the IC50 value could potentially
bring more useful information into our model like the strength of the binding.
In order to pass the high-order features into out layers, we designed a feed-forward neural
network to perform and analyze the features passed from HLA Feature Extractor and Peptide
Feature Extractor. We first used a concatenate layer to merge features from peptide and HLA.
After this, we performed several dense layers (the regular deeply connected neural network
layer), dropout layers (layers which is used to prevent a model from overfitting), and activation
layers(LeakyReLu and linear layers) to further fully connect all the features. Eventually, our
model outputs one number to represent the binding affinity (IC50).
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Figure 3.4: MHCherryPan Network Architecture: (I) Peptide Feature Extraction. (II) MHC
Feature Extraction. (III) Affinity Prediction. (IV) Components of a convolutional Block

3.4

Pipeline

The MHCherryPan model for solving MHC-peptide binding prediction problems follows a
straightforward pipeline, as shown in figure 3.4. As discussed, the model consisted three parts:
peptide feature extraction, HLA Feature extraction, and affinity prediction. When the paired
input data goes through the model, the HLA extractor module will extract abstract features from
HLA sequences, and the peptide extractor module will extract features from peptide sequences.
In the end, the affinity prediction module would concatenate the features from both modules
and produce the prediction.
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Figure 3.5: Model Training: Forward and Backward Propagation, replicated from original
article[15].

3.5

Model Training

Training the neural network is to learn the values of parameters(weights and biases) for models.
It is extremely significant for improving the model performance, and training is done by an
iterative process of forward propagation (forward information flow), and backward propagation
of the information by the layers of neurons. Figure 3.5shows the process of model training.
Forward propagation occurs when inputting the training data into the model, and these
data go through the whole network for their labels or predictions to be computed. By doing
this, the input data would be transformed through all the layers of network, and all its neurons
have applied their transformation, the predicted label or result will be produced by the model
or the final layer.
A loss function is used to calculate the error or the loss so we can compare and measure
how close or distinct our prediction result was compared with the correct result (true label).
The goal for training the model is to have the cost or loss function as small as possible, which
means there is little or no divergence between predict label and expected value (true label). In
order to achieve the goal, the weights of the neurons or the network will gradually be adjusted
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along the direction where the loss function is smaller and smaller. One of the common loss
functions used for regression prediction is mean square error, which is also the loss function
used to train this model. The function definition is shown as below (3.1).
n

L=

1X
(YIC50 (i) − ŶIC50 (i) )2
n i=1

(3.1)

YIC50 (i) represents the true value and ŶIC50 (i) stands for the predict value.
Back propagation is a widely used algorithm to calculate the derivative (gradient) of the
cost function with respect to the weight matrices. After the loss has been computed, this
information is spread backward. The loss propagates to all layers that relate to the output result
beginning from the output layer. Nevertheless, the hidden layers merely acquire a proportion of
the total loss, according to how relative contribution that each layer has devoted to the former
output. This process is repeated until the loss is minimum.

Chapter 4
Experiment setup
In this chapter, we discussed our experiment setup, including the datasets that we use, model
training, model validation, performance evaluation methods and some experiment implementation details.

4.1

Dataset

This section would discuss the datasets we used. The data is the result of a combination of
two datasets. We obtained the MHC sequential data from EBI, and we collected experimental
binding data from IEDB. These two sets were then combined to create a single set to use for
training and validation. We would discuss those databases we used and how we collect data in
detail.

4.1.1

EBI

The EMBL Outstation-European Bioinformatics Institute (EBI) is a center for research and services in bioinformatics, which manages and makes available a wide range of the databases of
biological data including nucleic acid, protein sequences, and macromolecular structures. For
this thesis, we are particularly interested in the IPD-IMGT/HLA Database, which was used
31
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to collect details for the MHC molecules. The Immuno Polymorphism Database (IPD)- International ImMunoGeneTics (IMGT) Databases provides a database specialized for sequences
of the human major histocompatibility complex (MHC). This database utilizes the official sequences names, which are from the WHO Nomenclature Committee For Factors of the HLA
System[30]. The IPD-IMGT/HLA Database works as a part of the international ImMunoGeneTics project (IMGT).[30]. We obtained 2895 pre-aligned HLA sequences of length 180
amino acids from EBI.

4.1.2

IEDB

The Immune Epitope Database (IEDB)[9] provides a broad set of experimentally characterized peptides and peptide-MHC binding affinities data publicly for research use. Database
entries are curated from published literature, and numerous affinities are conducted based on
immunofluorescent assays. These affinities are represented as an IC50 value, the half-maximal
inhibitory concentration in nano-molar (NM) units of peptide to MHC molecules. A total of
approximately 1,100,000 examples from MHC ligand assays was available as of Aug 2019,
spanning multiple mammalian and avian species.
The training dataset is downloaded from the IEDB database (http://tools.iedb.org/
main/datasets). All training data is labeled by IC50 binding affinity values. The HLA sequences were obtained from the EBI database, and all the sequences are already in alignment in
180 aa length. We trained our model on peptides binding to HLA-A, HLA-B and HLA-C alleles with available HLA sequences. The training dataset contains 202091 peptide-HLA binding
peptides covering 42 HLA-A alleles (132255 samples), 49 HLA-B alleles (66704 samples),
and 10 HLA-C alleles (3132 samples). All peptides in the training set consist of 8-15 amino
acid residues.

4.2. Data pre-processing and pre-analysis
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Data pre-processing and pre-analysis

In this section, we would further look into the peptide-hla data since the data is always the
fundamental key for building up the model. Also, the more we comprehend our data, the better
we could do to build up our model. We would introduce the pre-processing methods, data
pre-analysis, and data visualization for our peptide-hla data.

4.2.1

Peptide-HLA data pre-processing

Figure 4.1: MHC Training Data

Data preprocessing is a data processing method to transform experimental data into a clean
format, which could help to prevent some data issues such as incomplete data, data with lacking specific attributes, and data with errors[25]. The experimental peptide-HLA data we collected from IEDB contained many features(in total 98 fields), and many of them are irrelevant for model training. Therefore, the first step was to remove those irrelevant features
from the dataset. When filtering the dataset, we kept only three fields (out of 98): mhc - the
MHC name (e.g., HLA-A*01:01) using nomenclature for factors of the MHC System(http:
//hla.alleles.org/nomenclature/naming.html), peptide - the peptide amino acid sequences information for hla-peptide data, IC50(nM) - the binding affinity measurement by
IC50 (The half maximal inhibitory concentration). Figure 4.1 illustrates an example of MHC
training data. We also remove any entry with invalid data like sequences with uncertainty in
the amino acids (see section 3.2.1).

34

Chapter 4. Experiment setup
Besides, We remove the sequences from the dataset that is rare enough. As mentioned, the

peptide-HLA data varies by length of the peptide. The length of peptides for the majority of
the data is around length 8 to length 15 aa (Please see figure 4.4 for more specific statistics).
Therefore, we filtered out those data where the length is smaller than eight or greater than
15 due to that the Peptide-HLA data with those lengths don’t have enough data. Figure 4.2
indicates the statistics summary (including total counts, means, Standard deviation, minimum,
25%, 50%, 75%, maximum) for our training dataset. Before we encode our data as the input to
train our model, we also implemented data analysis and visualization to learn more about the
data.

Figure 4.2: The statistics summary for training dataset
The Y IC50 is the constructed feature from IC50 using the log function. The details can be
found in subsection 4.4.2.

4.2.2

HLA Sequences

We downloaded all the training data from IPD - IMGT datasets[30]. But since the goal is to
build a pan-specific model, the amino acids sequences information for HLA are also necessary.
HLA sequences have different lengths. Alignments for those sequences are necessary due to
most of machine learning models require the fixed-length input. Therefore, the pre-aligned
HLA sequences were collected from the EBI database and the length is 180 aa[33].
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Figure 4.3: Pie chart of binding or not for MHC Training Data.[38]: The blue part is for
”not binding” data and the orange part is for ”binding” data.

4.2.3

Data pre-analysis and visualization

In order to have a better understanding of our data, we did a comprehensive analysis and
visualization for our training data from IEDB.
We firstly group our data by ”binding” or ”not binding.” As Figure 4.3 indicates, there are
30.4% training data that are labeled ”binding” and 69.6% labeled ”not binding.” In reality, the
ratio of positive vs negative was in the range of 1.3% vs 98.7% ([4]). This difference could
be illustrated by the selection process used to select candidates on which the experiments are
performed that contribute to those online datasets [4]. It is reasonable that lots of experiments
are done with those samples that are more likely to yield a positive result [4]. Therefore, we get
imbalanced data. In order to solve this, we used the Area under the ROC curve (AUC) instead
of accuracy to measure our model performance. This is due to that accuracy only measures
the number of correctly predicted samples over the total number of samples, and it could be
misleading for unbalanced data since it will be more sensitive to the class of more data. In this
case, the AUC can be used as a better model evaluation method since it could also consider the
precision and recall. The AUC would be discussed in more detail in the section 4.4.2.
Regarding the mhc/hla peptide binding mechanisms, there are multiple features that play a
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Figure 4.4: Training data distribution by peptide length.

role in it. Among them, two of the significant features which would have a big influence on
model performance are hla alleles and peptide sequential data. Therefore, we grouped our data
distribution by hla alleles and peptide sequences to have a better understanding of our data.
As we mentioned previously, the length of peptide is an important feature regarding the
HLA peptide binding mechanism. Therefore, we grouped our data by the peptide length, and
figure 4.4 is an overview of the hla-peptide data distribution by peptide length. As shown in
figure 4.4, the numbers of training samples varies greatly. As we can see from the figure 4.4,
most data concentrated in length 9, which is far more than any other length. The second most
hla-peptide data is in length 10. As we can see from the figure, the majority of data stays in
length 9 and length 10, which we would perform a more detailed analysis in the next subsection.
The rest length data (length 8, 11, 12, 13, 14, 15) has less data compared with length 9 and
length 10. Therefore building up a reasonable model which considering the data distribution in
length would be significant. This is also one of the reasons why we choose the RNN. Due to
the majority of data is in length 9 and length 10, we also analyze the frequency of amino acids
in peptide.

4.2. Data pre-processing and pre-analysis

Figure 4.5: Binding Affinity Distribution by Alleles
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Figure 4.5 indicated the affinity value(transformed IC50) distributions by different hla alle-

les. The x-axis is the target value and it represents the binding affinity between peptide and hla
which will be inputted into our model(the transformed function is in 4.4.2 Metrics and Mathematical Function subsection) for training. We visualize the result through box plot. Using
the box plot, we can compare the range and distribution of the affinity value for different hla
alleles. Each box in alleles shows the quartiles of the dataset while the whiskers extend to
show the rest of the distribution. An outlier is an observation that is numerically distant from
the rest of the data[42]. When reviewing a box plot, an outlier is defined as a data point that
is located outside the fences(”whiskers”) of the box plot. As the figure shows, alleles have
different binding affinity distribution. The neighboring alleles (the similar alleles) in the table
tend to have the more similar distributions of binding affinities distribution.

4.2.4

The Amino Acid Enrichment for peptide-hla binding data

We also filtered out the non-binding data and analyzed HLA-binding binding data through
statistics-based visualization using bar chart and iceLogo, examining amino acid abundance at
each position of the 9-aa and 10-aa peptides.
Figure 4.6 and Figure 4.7 show the frequencies of each position of 9-aa peptides for HLApeptide ligands. As we can see from the figure, for all the HLA allele types in this data set,
the majority anchor positions were at the position 2, position 3, and the C-terminal position.
In addition, we also found that the particular amino acid frequency at the C-terminal position
correlated strongly among all the positions. Those results are in accordance with the similar
statistic analysis we could find in Faridi’s paper in 2018 [7].

4.2.5

Encoding

After filtering, analyzing, and visualizing the data, the next step is to transfer the raw data,
which is the amino acid sequence into the encoded data that the machine learning model could
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Figure 4.6: Motif analysis for 9-mer peptides[38]: showing the percentage of enriched amino
acid at each position for hla-peptide binding data.
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Figure 4.7: Motif analysis for 10-mer peptides showing the percentage of enriched amino
acid at each position for hla-peptide binding data.
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take as the input. As mentioned in section 2, we tested different encoding matrices and finally
decided to use the BLOSUM62 Matrix to encode the pair of peptide-HLA sequences into the
those NumPy arrays (A numpy array is the standard representation for numerical data [37]).
The comparison result of different encoding metrics would be illustrated in the result section.
Regarding the y label (IC50 values), due to our goal is to make a regression model to predict
the binding affinity but the IC50 values in our datasets varies too much (from 0 to 80000NM),
we use the equation as mentioned in subsection 4.4.2 to transfer our data into y value in the
range of 0-1, which could help to input our data into the model.

4.3

Model Learning

In this section, we give some more details regarding the model learning. We introduce training
the model, implementing the training experiment, and preventing overfitting.

4.3.1

Model training and preventing overfitting

We used training datasets and validation datasets to train our model. Firstly, we split all our
training data randomly into training sets and validation sets by following a 4:1 ratio. Training
datasets are used to fit or train the parameters of our model. The validation dataset would
be used to give an unbiased evaluation for our trained model. By using validation sets, we
could choose the best performance model from all the training models (with different trained
parameters). The table 5.1 indicated the training AUC and validation AUC for our model.
The MHCherryPan model was implemented with the Keras. Stochastic gradient descent
(SGD) is utilized as the optimizer. We trained our model with learning rate decay and used
an early stop approach to prevent overfitting. The initial learning rate (a tuning parameter in
an optimization algorithm that determines the step size at each iteration while moving toward
a minimum of a loss function [46]) is 0.005, and the momentum factor is 0.6. It is scheduled
to decrease the learning rate if AUC has not increased within 20 epochs. We set the minimum
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learning rate as 0.00002. The training process stops if the loss on the validation set has not
decreased within 50 epochs.
In addition to utilizing the early-stop strategy, we also applied the following methods to
prevent overfitting. We designed several Drop Out layers in our model to reduce overfitting
by introducing discrete noise during training. We also used multiple Batch normalization to
re-parameterize the hidden unit activation in order to increase convergence speed and make the
output stochastic, creating a regularizing effect[16].

4.3.2

Implementation

The entire programming for the model is done in Python 3.7. Pandas library package (version
0.24.1) is used for data preprocessing, and Keras library package (version 2.2.4) is utilized for
building the model.
The model training is done through Sharcnet server. Regarding the resources, as Figure 4.8
shows, 2 GPU and 4 CPU cores are used. The memory usage is allocated for 40GB. The details
regarding the used package and sharcnet server can be found in section 4.5.

Figure 4.8: Job script for Model training

4.4

Performance Evaluation

In this section, we introduce the test benchmark dataset and how to evaluate the performance
of our model by using the test dataset.

4.4. Performance Evaluation
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Test Benchmark Dataset

In order to evaluate our model performance, we use a public test benchmark dataset, which
is provided by IEDB to test several popular hla-peptide binding algorithms. The test benchmark dataset and training dataset are distinct with each other. The test benchmark dataset is
downloaded from IEDB’s weekly benchmark dataset, and the date is ranged from 2014-03-21
to 2019-05-26 (http://tools.iedb.org/auto_bench/mhci/weekly). In case that duplicate peptides may appear in both the training and testing dataset downloaded from IEDB, we
eliminated all duplicate peptides from the benchmark testing dataset.

4.4.2

Metrics and Mathematical Function

In this thesis, both Area under the curve (AUC) and Spearman’s rank correlation coefficient
(SRCC) are used as the evaluation metrics to compare the performance of our model with the
public benchmark results of other current widely-used models from IEDB [32]. Both AUC and
SRCC are calculated using the Scikit learn package for Python3.
Area under the receiver operating characteristic curve (AUC)
AUC is the area under the resulting curve of the positive rate and false positive rate at each
possible score threshold.It is in a sense a broader metric, testing the quality of the internal
value that the classifier generates and then compares to a threshold. As Figure 4.9 indicates,
the false positive rate and the true positive rate(precision) are calculated for each possible score
threshold, and the final metric is the area under the resulting curve.[3]

True positive rate (or sensitivity or recall) =

True negative rate (or Specificity) =

True positive
true positive + false negative

True Negatives
True Negatives + False Positives

(4.1)

(4.2)
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False positive rate =

False Positive
False Positive+True Negative

Precision or positive predictive value =

True Positive
True Positive+False Positive

(4.3)

(4.4)

Figure 4.9: AUC Curve.: Taken from Receiver operating characteristic - Wiki [40]
A true positive (TP) defines as an outcome in which the model correctly predicts the positive class. Also, a true negative is an outcome in which the model correctly predicts the
negative class.[45] A false positive (FP) defines as an outcome in which the model wrongly
predicts the positive class. A false negative is an outcome in which the model wrongly predicts the negative class.[45] The true positive rate, true negative rate, and false positive rate are
calculated as formula 4.1, 4.2, and 4.3. Sensitivity (which is also called the true positive rate
or the recall) measures the proportion of actual positives that are correctly identified as such
[48]. For instance, the percentage of infected people who are correctly identified as having the
condition [48]. Specificity (which is called the true negative rate) measures the proportion of
actual negatives that are correctly identified as such. For example, the percentage of uninfected
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people who are correctly identified as not having the condition [48].Positive rate is the sum of
the true positive rate and the false positive rate. precision is the fraction of relevant instances
among the retrieved instances, while recall (or sensitivity) is the fraction of the total amount of
relevant instances that were actually retrieved. [47].
The reason why we prefer AUC is due to two points: first, AUC and Spearman’s rank
correlation coefficient are the standard measurements which are used on the IEDB benchmark
website. It would be appropriate to use the same measurements as the benchmark website used.
Second, AUC is more sensitive to imbalanced class. As explained, AUC considers true positive
rate and false positive rate in the measurement, which in that sense may be a better summary of
the performance of a classifier since it incorporates different aspects of the performance into a
single number. Regarding accuracy, it may not be suitable for the imbalanced class. Accuracy
would be favor for the majority class, which is not what we want. For example, if we have an
imbalanced dataset where 95 are positive and 10 are negative, in this case, the classifiers could
always predict ”positive” to achieve the high accuracy. But this is not what we want. We want
a classifier to distinguish two classes instead of always guessing the ”majority” result. On the
other hand, AUC is better since it consider true positive rate and false positive rate. In addition,
some other measurements may also be acceptable like Precision-Recall curves. But since we
want to compare our results with the results reported on benchmark website, it may be more
appropriate to use the same measurement (AUC) as website used.
Spearman’s rank correlation coefficient (SRCC)
The Spearman correlation coefficient is a method to summarise the direction and strength
of a relationship between two variables.[50] The Spearman correlation coefficient is to measure
the monotonic relationship between distributed variables. It represent the rank correlation between target and predicted values for quantitative measurements. The pair we used to measure
here is the target value and predicted value. It defines as below:
P
6 di2
ρ=1−
n(n2 − 1)

(4.5)
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d is the pairwise distances of the ranks of the variables and n is the number of samples.
There is an another similar method is called Pearson coefficients. It is also used to measure
the relationship between two variables. But the difference is that the Pearson coefficients measure the linear relationship between two continuous variables while the Spearman correlation
evaluates the monotonic relationship between two continuous or ordinal variables[50]. The
monotonic relationship means the variables tend to change together, but may not at a constant
rate. Since what we measure is the target value and predict value, we believe the monotonic
relationship may makes more sense instead of only linear relationship. Also, as mentioned
previously, another big consideration is that SRCC is the measurement used by the benchmark website. Those are the reasons why we choose the SRCC instead of Pearson coefficients.
However, this is just our preference. Some model like MHCflurry used Kendall rank correlation coefficient (a similar matrix like SRCC to measure the monotonic relationship), AUC
and Pearson coefficients for model performance evaluation. From their published result, the
Pearson coefficients have the similar results as other two measurements.
Binding Affinity(IC50 )
The IC50 value in our HLA-peptides training dataset covered a large range from 0 to
80000nM. IC50 value is used as the an experimental measurement for binding affinity. The
higher the IC50 value stands for, the lower the binding affinity. In order to fit all data smoothly
into the model and prevent the gradient explosion problem from training the deep neural network, we transform the IC50 into the regression y value using the equation below. We define
MaxIC50 as 50000nM.

YIC50








0
= 





1 − log MaxIC50 IC50

if IC50 > MaxIC50
(4.6)
if IC50 ≤ MaxIC50

In order to obtain the predicted label (whether binding or not), we use a common threshold
500nM for IC50 , for which many other popular models used and previous studies[31] demonstrated 500 nM as an MHC affinity threshold for HLA class I. We use binary label 0 - not
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binding and 1 - binding.







0 if IC50 > 500nM
label = 





1 if IC50 ≤ 500nM

(4.7)

The overall loss L is the sum of the regression loss defined as the Mean Square Error.
n

1X
(YIC50 (i) − ŶIC50 (i) )2
L=
n i=1

(4.8)

YIC50 (i) represents the true value and ŶIC50 (i) stands for the predict value.

4.5

Technologies and Tools

This section gives an overview of the tools used throughout the various parts of this thesis. All
code was written in Python 3.7.
Keras (2.2.4) is an open-source, high-level neural networks API written in Python. It can
be configured to use Tensorflow, CNTK or Theano as backend. We used the default backend
which is Tensorflow. Keras greatly simplifies the code needed to design, train and evaluate
Neural Networks, while retaining the performance of more complicated libraries. This makes
it a great tool for research.
Tensorflow (1.14.1) was used as the underlying library for Keras. It is an open-source
library for numerical computations such as neural networks. It was originally designed by
Google to perform a deep neural network and machine learning research.
Pandas (0.24.1) was used to reading, parsing and saving pre-processed files. It is an opensource library providing multiple data structures and data analysis tools which are commonly
used in machine learning.
NumPy (1.13.1) is a package for scientific computing in Python. It is part of the SciPy
(0.19.1) ecosystem. Its N-dimensional array structure is used as the main data container for the
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various mathematical libraries used throughout the thesis.
SHARCNET was used as the server for training our model. It is initiated by universities
in Ontario, Canada to accumulate funding together to purchase supercomputer systems, and it
could be shared and used by university researchers to perform research, instead of individually
purchasing smaller systems.[49]

Chapter 5
Result and discussion
In this chapter, firstly, we discuss the experimental results, including the model performance on
validation sets using different encoding matrix. Secondly, we compare the performance of our
model with current popular models including as follows: pan-specific algorithms: NetMHCPan3.0, NetMHCPan4.0, and PickPocket, allele-specific algorithms: SMM, NetMHC3.4, NetMHC4.0,
ARB, MHCflurry and AMMPMBEC, and consensus algorithms: IEDB Consensus and netMHCcons.

5.1

Experimental results on different encoding metrics

In this section, we discussed the model performance on the validation dataset by using different
encoding metrics. Finally, selecting Blosum62 as the final encoding matrix.

5.1.1

BLOSUM Matrix

The figure 5.1 illustrates all the BLOSUM matrix which we tested for our model. It includes
blosum 60, blosum 62, blosum 70, blosum 80, and blosum 90. BLOSUM stands for Block
Substitution Matrices. It computes pairwise amino acid alignment counts and it counts amino
acid replacement frequencies directly from columns in blocks. The number XX after BO49
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Figure 5.1: Blosum Matrix: from top to bottom: blosum 60, blosum 62, blosum 70, blosum 80, and blosum 90. The matrix is downloaded from ftp://ftp.ncbi.nlm.nih.gov/
blast/matrices/
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LUSM indicates the sequences that are XX% similar are clustered during the construction
of the BLOSUM matrix. BLOSUM matrices with high numbers are designed for comparing
closely related sequences, while those with low numbers are designed for comparing distantly
related sequences[39].

5.1.2

Results on different blossom matrix

The table 5.1 indicates the model performance using different encoding matrix including blosum60, blosum62, blosum65, blosum70, and blosum90. Regarding my model, all blosum
matrix performances similarly and blosum62 gives a slightly better model performance. Those
blosum matrix were downloaded from NCBI website(ftp://ftp.ncbi.nih.gov/blast/
matrices/ )

Encoding Matrix

AUC

SRCC

Blosum60
Blosum62
blosum70
blosum80
blosum90

0.833
0.843
0.839
0.842
0.840

0.734
0.742
0.738
0.748
0.743

Table 5.1: Validation Experiment results for the MHCherryPan model trained on IEDB dataset.
From the table 5.1, it can be seen that for the blosum 60, blosum 70, blosum 80, and
blosum 90, the highest AUC (blosum62) is 84.3% and the lowest (blosum60) is 83.3%. Also,
the difference is very small (0.1%). The reasons why We finally choose the blosum 62 as the
final encoding matrix is due to the following two points: firstly, it gives us the slighter better
AUC performance comparing with other matrices. Second, BLOSUM-62 matrix is a more
widely used matrix, and it is among the best for detecting the weakest protein similarities. It
is also the default matrix in lots of protein alignments such as protein BLAST. Although we
choose the Blosum62 as the default encoding matrix, programming is designed to be flexible,
and it can easily switch to other encoding matrices as well.
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5.2

Experimental results on Benchmark testing dataset

In order to compare our model performance with other popular HLA-binding prediction models, we evaluated our model on the public IEDB weekly benchmark datasets where a set of
top algorithms have been evaluated with the published results. Those top algorithms include
as follows: pan-specific algorithms: NetMHCPan3.0, NetMHCPan4.0, and PickPocket, allelespecific algorithms: SMM, NetMHC3.4, NetMHC4.0, ARB, MHCflurry and AMMPMBEC,
and consensus algorithms (results are based on several different algorithms): IEDB Consensus
and netMHCcons. We firstly trained our MHCherryPan model on the training datasets. Then
we evaluated our trained MHCherryPan on all the available IEDB weekly benchmark datasets.
AUC and SRCC are used as the metrics to compare the performance.
Table 5.2 summarized the performance of different models on a total of 77 IEDB benchmark testing datasets. For each IEDB dataset, we highlighted the highest AUC scores in red
and the highest SRCC scores in green. Then we summed up the number of datasets where each
algorithm achieved the highest scores and we put them at the bottom row of the table. It can be
observed that our MHCherryPan acquired the highest AUC scores in 29 records out of a total
of 77 testing datasets. In 48 datasets where our MHCherryPan didn’t acquire the highest AUC
scores, there are 14 records on which the AUC scores of MHCherryPan are very close to the
highest AUC scores within a small margin around 0.2. Comparing with all other algorithms
regarding AUC in the benchmark table, mhcflurry and our model ranked the first and second,
obtaining the similar numbers of 30 and 29. In terms of SRCC, MHCherryPan obtained the
highest scores on 17 records, which ranked the second. Among pan-specific models (NetMHCPan3.0, NetMHCPan4.0, and PickPocket), our model performed much better in both AUC and
SRCC, and our numbers of highest AUC and SRCC are almost double the other pan-specific
algorithms.
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Table 5.2: Performance Evaluation on IEDB Benchmark Database
Pan-specific

Allele-specific

Ensemble

Measure
MHCherryPan NetMHCpan3 NetMHCpan4 PickPocket
HLA

IEDB Ref Type Len Count auc

HLA-B*57-01 1029061

ic50

9

HLA-B*57-01 1028554

ic50

HLA-C*05-01 1028230

ic50

HLA-C*07-02 1028232

ic50

SMM

NetMHC3.4 NetMHC4

ARB

SMMPMBEC mhcflurry IEDBCons NetMHCcons

srcc

auc

srcc

auc

srcc

auc srcc

auc srcc auc

srcc

auc srcc auc srcc auc

srcc

auc srcc auc srcc auc

srcc

0.64

0.84

0.6

0.82

0.57

0.88 0.67 0.85 0.62 0.8

0.62

0.74 0.56 0.45 0.16 0.79

0.56

0.8 0.66 0.81 0.58

0.57

0.96

0.7

0.87

0.64

0.88

0.6

0.85 0.44 0.77 0.33 0.94

0.52

0.96 0.53 0.63 0.12 0.77

0.29

0.97 0.62 0.77 0.33 0.92

0.56

172 0.98

0.85

0.98

0.89

0.97

0.88

0.95 0.84

0.94

0.99 0.92

-

-

0.99

0.9

0.91 0.8

0.92

-

-

26

0.87

9

53

9

1

0.91

1

1

0.91

0.8

1

9

140 0.92

0.78

0.96

0.81

0.97

0.83

0.91 0.76 0.96 0.92 0.97

0.89

0.95 0.85

0.97

0.91

0.86 0.67 0.96 0.92 0.97

0.88

HLA-A*24-02 1026840 binary 9

357 0.91

0.49

0.86

0.43

0.87

0.44

0.84 0.41 0.84 0.4 0.87

0.44

0.86 0.43 0.83 0.4 0.84

0.4

0.86 0.43 0.85 0.42 0.87

0.44

HLA-A*24-02 1026840

9

20

0.74

0.34

0.67

0.3

0.66

0.27

0.76 0.45 0.74 0.4 0.59

0.21

0.62 0.23 0.44 0.05 0.75

0.38

0.75 0.39 0.73 0.37 0.59

0.2

HLA-B*27-04 1029125 binary 9

21

0.98

0.78

0.99

0.8

0.99

0.8

0.83 0.53

0.95 0.73

0.94

0.72

HLA-A*30-02 1026840 binary 9

360 0.87

0.59

0.78

0.45

0.78

0.45

0.75

0.4

0.73 0.36 0.75

0.4

0.75 0.4 0.65 0.25 0.72

0.35

0.83 0.52 0.75 0.4

0.77

0.43

HLA-A*30-02 1026840

ic50

9

56

0.67

0.34

0.48

-0.02

0.49

-0.01

0.4

-0.1 0.54 0.12 0.59

0.13

0.54 0.03 0.64 0.27 0.52

0.07

0.8 0.58 0.55 0.08 0.51

0.05

HLA-A*30-02 1026840

t1/2

9

56

0.46

0.04

0.48

0.03

0.5

0.05

0.47 -0.01 0.5 0.07 0.55

0.19

0.48 0.07 0.52 0.15 0.53

0.12

0.57 0.19 0.48 0.07

0.5

0.09

ic50

-

-

-

-

-

-

-

-

-

-

-

-

HLA-A*02-02 1028790

ic50

9

55

0.84

0.69

0.75

0.59

0.76

0.61

0.72 0.53 0.71 0.56 0.74

0.64

0.72 0.59 0.73 0.49 0.74

0.57

0.91 0.86 0.71 0.56 0.75

0.62

HLA-A*02-02 1024516

ic50

9
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0.86

0.7

0.78

0.6

0.79

0.62

0.7

0.69 0.55 0.74

0.65

0.72 0.6 0.76 0.51 0.73

0.57

0.93 0.86 0.68 0.56 0.75

0.63

HLA-B*27-05 1029125 binary 9

21

0.99

0.8

0.95

0.73

0.94

0.72

0.91 0.67 0.91 0.67 0.94

0.72

0.96 0.75 0.88 0.62 0.96

0.75

0.96 0.75 0.91 0.68 0.96

0.75

HLA-B*27-05 1031253

9

12

0.63

0.57

0.63

0.57

0.57

0.48

0.6

0.49 0.63 0.44 0.69

0.6

0.69 0.58 0.6 0.46 0.6

0.46

0.71 0.71 0.64 0.49 0.66

0.62

HLA-A*02-01 1033576 binary 9

27

0.9

0.5

0.87

0.46

0.88

0.47

0.89 0.48 0.89 0.48 0.92

0.52

0.91 0.51 0.78 0.35 0.89

0.48

0.9

0.88 0.47

0.9

0.5

HLA-A*02-01 1028554

ic50

9

44

0.74

0.46

0.88

0.71

0.88

0.72

0.88 0.51 0.89 0.58 0.82

0.62

0.81 0.6 0.76 0.51 0.86

0.55

0.91 0.63 0.84 0.5

0.89

0.69

HLA-A*02-01 1028553

ic50

ic50

0.5

0.5

9

22

1

0.61

0.85

0.59

0.85

0.57

0.83 0.58 0.85 0.59 0.91

0.7

0.92 0.63 0.9 0.69 0.83

0.62

0.97 0.76 0.85 0.58 0.92

0.64

HLA-A*02-01 1029824 binary 9

77

0.6

0.16

0.57

0.1

0.56

0.09

0.55 0.08 0.57 0.1 0.57

0.11

0.58 0.12 0.52 0.04 0.57

0.1

0.61 0.17 0.58 0.12 0.56

0.09

HLA-A*02-01 1033071

ic50

9

112

0.9

0.81

0.88

0.82

0.88

0.81

0.85 0.78 0.87 0.8 0.88

0.81

0.88 0.82 0.85 0.79 0.87

0.81

0.88 0.82 0.87 0.81 0.88

0.81

HLA-A*02-01 1026371

t1/2

9

85

0.8

0.54

0.81

0.57

0.81

0.57

0.79 0.54 0.81 0.56 0.82

0.58

0.81 0.57 0.81 0.56 0.81

0.56

0.82 0.6

HLA-A*02-01 1027079 binary 9

16

0.71

0.34

0.8

0.48

0.84

0.54

0.8

0.48 0.75 0.39 0.76

0.42

0.76 0.42 0.78 0.45 0.75

0.39

0.82 0.51 0.73 0.37
0.85 0.6

0.8 0.52 0.82

0.57

0.8

0.48

0.84 0.58 0.83

0.56

0.51 0.56 0.57

0.61
0.73

HLA-A*02-01 1027588 binary 9

19

0.81

0.53

0.85

0.6

0.84

0.58

0.74 0.42 0.84 0.58 0.84

0.57

0.86 0.62 0.77 0.47 0.85

0.6

HLA-A*02-01 1028790

ic50

9

55

0.68

0.67

0.58

0.61

0.58

0.63

0.66 0.59 0.56 0.63 0.57

0.61

0.56 0.61 0.57 0.58 0.55

0.61

HLA-A*02-01 1031894

ic50

9

431 0.81

0.57

0.9

0.74

0.9

0.74

0.78 0.57 0.82 0.65 0.88

0.72

0.88 0.72 0.76 0.54 0.82

0.65

0.86 0.75 0.82 0.64 0.88

HLA-A*02-01 1024516

ic50

9

51

0.74

0.7

0.63

0.65

0.63

0.67

0.66 0.59 0.64 0.69 0.64

0.67

0.63 0.67 0.65 0.66 0.63

0.68

0.71 0.75 0.57 0.62 0.63

0.67

HLA-A*02-01 1028928 binary 9

13

0.91

0.51

0.95

0.57

0.95

0.57

0.93 0.54 0.95 0.57 0.95

0.57

0.95 0.57 0.95 0.57 0.95

0.57

0.95 0.57 0.95 0.57 0.95

0.57

HLA-A*02-01 1027471 binary 9

45

0.94

0.51

0.84

0.4

0.84

0.4

0.86 0.43 0.85 0.42 0.85

0.41

0.86 0.43 0.85 0.41 0.85

0.42

0.9 0.47 0.85 0.41 0.86

0.42

HLA-A*02-01 1026840 binary 9

357

0.9

0.57

0.91

0.57

0.9

0.57

0.89 0.55

0.9 0.57 0.89

0.55

0.91 0.58 0.9 0.56 0.9

0.57

0.91 0.58 0.91 0.58

0.9

0.57
0.32

-

-

HLA-A*02-01 1026840

ic50

9

24

0.65

0.22

0.66

0.38

0.66

0.35

0.68 0.38 0.64 0.33 0.59

0.26

0.64 0.33 0.69 0.4 0.61

0.29

0.71 0.47 0.56 0.19 0.65

HLA-A*02-01 1026840

t1/2

9

24

0.72

0.45

0.76

0.48

0.73

0.43

0.67 0.39 0.75 0.38 0.69

0.32

0.76 0.41 0.71 0.45 0.73

0.35

0.75 0.48 0.69 0.28 0.72

0.4

HLA-A*02-01 1028285

t1/2

9

881 0.85

0.65

0.86

0.71

0.87

0.72

0.84 0.68 0.85 0.7 0.85

0.69

0.86 0.7 0.82 0.65 0.85

0.69

0.87 0.71 0.84 0.68 0.86

0.71

HLA-C*03-03 1028228

ic50

9

163 0.95

0.88

0.92

0.83

0.92

0.82

0.9

0.81 0.95 0.85 0.93

0.85

0.95 0.87

0.94

0.84

0.87 0.78 0.95 0.85 0.93

0.84

HLA-B*07-02 1028554

ic50

9

52

0.92

0.74

0.79

0.63

0.8

0.66

0.74

0.7

0.85 0.66 0.88

0.7

0.83 0.67 0.76 0.65 0.86

0.7

0.92 0.86 0.82 0.59 0.86

0.73

HLA-B*07-02 1028553

ic50

9

22

0.88

0.62

0.89

0.67

0.88

0.73

0.89 0.62 0.89 0.62 0.92

0.76

0.89 0.65 0.88 0.55 0.88

0.62

0.91 0.68 0.88 0.67 0.91

HLA-B*07-02 1031253

ic50

9

13

1

0.93

1

0.97

1

0.98

HLA-B*07-02 1026371

t1/2

9

43

0.93

0.81

0.97

0.86

0.98

0.87

HLA-B*07-02 1028928 binary 9

12

1

0.65

1

0.65

1

0.65

1

0.87

1

0.96

1

0.88 0.65 0.96 0.79 0.96
1

0.65

1

0.65

1

0.96
0.84
0.65

1

0.98

-

1

-

0.89

1

0.94 0.82 0.78 0.53 0.96
1

0.65

1

0.65

0.97
0.81

1

0.65

1

0.96

1

0.97

1

0.96 0.85 0.96 0.79 0.95
1

0.65

-

-

1

0.66

1

0.72
0.97
0.84
0.65

HLA-B*07-02 1026840 binary 9

296 0.95

0.43

0.89

0.37

0.89

0.38

0.88 0.36

0.9 0.39 0.9

0.38

0.9 0.38 0.88 0.37 0.9

0.39

0.89 0.38 0.89

0.38

HLA-A*68-02 1028790

ic50

9

55

0.86

0.63

0.81

0.54

0.81

0.54

0.8

0.45 0.81 0.54 0.83

0.56

0.83 0.55 0.76 0.45 0.8

0.52

0.83 0.58

0.8 0.53 0.83

0.55

HLA-A*68-02 1024516

ic50

9

51

0.9

0.68

0.85

0.58

0.86

0.58

0.86 0.54 0.83 0.56 0.86

0.59

0.86 0.59 0.8 0.47 0.83

0.55

0.86 0.6

0.83 0.56 0.85

0.58

HLA-C*04-01 1028229

ic50

9

153 0.97

0.52

0.94

0.48

0.95

0.49

0.85 0.39 0.97 0.56

0.58

0.59

0.85 0.4

0.97 0.55

0.59

HLA-B*35-01 1028554

ic50

9

56

0.82

0.54

0.67

0.4

0.66

0.36

0.5

0.2

0.81 0.5

0.7 0.29 0.64

HLA-C*03-04 315209

t1/2

9

14

0.8

0.29

1

0.88

1

0.86

0.87 0.72

HLA-A*03-01 1031253

ic50

9

14

1

0.78

0.93

0.77

0.96

0.8

0.96 0.71 0.87 0.69 0.89

0.73

0.96 0.79 0.71 0.47 0.91

0.75

0.96 0.83

HLA-C*14-02 1028234

ic50

9

218

0.9

0.8

0.87

0.77

0.86

0.75

0.83 0.67 0.87 0.77 0.93

0.88

0.91 0.81

0.88

0.78

0.88 0.74 0.88 0.77 0.91

0.85

HLA-B*38-01 1029957

ic50

9

27

0.95

0.78

0.95

0.81

0.97

0.79

0.97 0.78 0.99 0.84

1

0.84 0.98 0.82 0.65 0.1 0.99

0.84

0.95 0.8

1

0.84

HLA-B*27-03 315174 binary 9

11

0.79

0.48

0.82

0.54

0.89

0.66

0.89 0.66

-

-

-

-

-

-

-

-

0.5

0.96 0.78

-

-

0.89

0.66

HLA-B*39-06 1029957

9

33

0.94

0.89

0.79

0.55

0.71

0.4

0.75 0.54

-

-

-

-

-

-

-

-

-

-

0.92 0.79

-

-

0.81

0.59

HLA-B*27-06 1029125 binary 9

21

0.84

0.57

0.77

0.45

0.73

0.39

0.8

-

-

-

-

-

-

-

-

-

-

0.87 0.62

-

-

0.75

0.42

HLA-A*30-01 1026840 binary 9

349 0.96

0.24

0.8

0.16

0.83

0.17

0.75 0.13 0.79 0.15 0.77

0.14

0.83 0.17 0.71 0.11 0.78

0.15

0.91 0.21 0.73 0.12 0.79

0.15

HLA-A*02-06 1028790

55

0.66

0.78

0.63

0.78

0.62

0.75 0.53 0.73 0.59 0.76

0.62

0.76 0.62 0.73 0.57 0.73

0.59

0.88 0.82 0.73 0.59 0.77

0.64

ic50

ic50

9

0.79

1

0.28 0.59 0.21 0.57

0.5

-

-

-

0.27
-

1

0.56

-

-

1

0.69 0.27 0.64 0.26 0.53
-

-

-

-

-

-

-

-

-

-

-

-

1

0.36

0.91

0.78

0.9 0.73 0.91

0.76

0.98 0.84
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Chapter 5. Result and discussion
Table 5.2: Performance Evaluation on IEDB Benchmark Database
Pan-specific

Allele-specific

Ensemble

Measure
MHCherryPan NetMHCpan3 NetMHCpan4 PickPocket

SMM

NetMHC3.4 NetMHC4

ARB

SMMPMBEC mhcflurry IEDBCons NetMHCcons

HLA-A*02-06 1024516

ic50

9

51

0.85

0.75

0.83

0.72

0.83

0.7

0.76 0.55 0.79 0.68 0.81

0.71

0.82 0.71 0.78 0.66 0.79

0.68

0.92 0.87 0.78 0.68 0.83

0.73

HLA-C*15-02 1028235

ic50

9

181 0.92

0.75

0.94

0.77

0.93

0.77

0.87 0.74 0.94 0.85 0.97

0.87

0.93 0.84

-

-

0.94

0.86

0.9

0.85

0

0.33 -0.25

-

-

1

0.76

0.17 -0.5

0.7

0.94 0.86 0.96

HLA-A*66-01 315312 binary 9

8

0.58

0.13

0.33

-0.25

0.42

-0.13

0.5

HLA-A*31-01 315312 binary 9

10

1

0.85

0.96

0.7

1

0.85

0.92 0.71 0.92 0.71 0.92

HLA-B*15-02 1027131 binary 9

14

1

0.71

1

0.71

1

0.71

HLA-B*44-03 1028554

ic50

9

46

0.72

0.58

0.64

0.6

0.58

0.56

0.64 0.43 0.75 0.47 0.65

0.56

0.74 0.65 0.56 0.25 0.76

0.55

0.69 0.77 0.84 0.56 0.64

0.55

HLA-C*12-03 1028286

ic50

9

172 0.87

0.75

0.71

0.54

0.72

0.55

0.65 0.43 0.57 0.52 0.69

0.65

0.72 0.65

0.61

0.61

0.81 0.63 0.57 0.52 0.71

0.63

HLA-A*68-01 1026840 binary 9

436 0.93

0.45

0.86

0.37

0.85

0.36

0.88

0.86 0.37 0.87

0.38

0.89 0.4 0.78 0.34 0.88

0.39

0.88 0.39 0.88 0.39 0.87

0.39

HLA-A*68-01 1026840

ic50

9

35

0.87

0.68

0.84

0.6

0.85

0.61

0.86 0.64 0.79 0.62 0.84

0.65

0.85 0.68 0.77 0.53 0.83

0.63

0.87 0.71 0.82 0.66 0.85

0.65

HLA-A*68-01 1026840

t1/2

9

35

0.29

-0.38

0.38

-0.2

0.38

-0.22

0.24 -0.46 0.25 -0.42 0.27 -0.41 0.28 -0.4 0.31 -0.39 0.25

-0.43

0.27 -0.38 0.26 -0.42 0.29

-0.35

HLA-A*02-03 1028790

ic50

9

55

0.76

0.58

0.71

0.54

0.71

0.53

0.77

0.68 0.52 0.67

0.51

0.66 0.49 0.68 0.5 0.69

0.53

0.69 0.58 0.66 0.42 0.69

0.54

HLA-A*02-03 1024516

ic50

9

51

0.8

0.6

0.75

0.56

0.74

0.57

0.77 0.47 0.68 0.53 0.68

0.54

0.67 0.53 0.73 0.54 0.69

0.54

0.72 0.62 0.66 0.42 0.71

0.56

HLA-C*08-02 1028233

ic50

9

87

0.9

0.7

0.92

0.77

0.92

0.76

0.83 0.65 0.92 0.79 0.96

0.88

0.92 0.81

0.79

0.79 0.6

0.86

1

0

0.5

0

0.71 0.91 0.58

0.4

0.5

0.5

1

0.71
0.71

0.92 0.71 0.88 0.64 0.92
1

0.71

1

-

-

0.72

-

-

1

0.92

0.71
0.71

1

-

0.5

0

0.5

0.92 0.71 0.92

0.71 0.97 0.67

1

0.92 0.79 0.96

0
0.71
0.71

HLA-B*07-02 1026371

t1/2

10

25

0.71

0.58

0.77

0.62

0.77

0.6

0.73 0.59 0.73 0.58 0.74

0.58

0.82 0.71 0.72 0.57 0.73

0.61

0.78 0.67 0.74 0.6

0.76

0.62

HLA-A*02-06 1028790

ic50

10

35

0.87

0.74

0.82

0.57

0.81

0.56

0.66 0.39 0.79 0.56 0.75

0.55

0.82 0.51 0.76 0.49 0.8

0.59

0.88 0.82 0.78 0.54 0.76

0.57

HLA-A*02-06 1024516

ic50

10

32

0.9

0.74

0.88

0.58

0.86

0.57

0.76 0.46 0.84 0.58 0.82

0.57

0.88 0.5 0.85 0.53 0.85

0.59

0.91 0.82 0.85 0.57 0.84

0.6

HLA-A*02-01 1033071

ic50

10

75

0.91

0.82

0.9

0.86

0.91

0.86

0.88 0.82 0.89 0.83 0.91

0.84

0.91 0.87 0.86 0.8 0.89

0.83

0.91 0.83 0.89 0.86

0.9

0.84

HLA-A*02-01 1024516

ic50

10

32

0.71

0.66

0.62

0.53

0.62

0.52

0.66 0.44 0.67 0.54 0.69

0.55

0.64 0.53 0.64 0.53 0.62

0.52

0.85 0.75 0.67 0.54 0.69

0.55

HLA-A*02-01 1026371

t1/2

10

22

0.56

0.04

0.54

0.12

0.56

0.14

0.56 0.07 0.56 0.14 0.58

0.19

0.52 0.06 0.53 0.11 0.55

0.11

0.58 0.16 0.55 0.13 0.56

0.15

HLA-A*02-01 1028790

ic50

10

35

0.72

0.59

0.6

0.43

0.6

0.43

0.65

0.65 0.47 0.67

0.45

0.64 0.44 0.64 0.44 0.59

0.45

0.84 0.67 0.66 0.46 0.68

0.44

HLA-A*02-01 1028285

t1/2

10

62

0.62

0.26

0.7

0.44

0.7

0.44

0.68 0.43 0.69 0.4 0.68

0.38

0.69 0.41 0.68 0.45 0.68

0.39

0.7 0.42 0.68 0.4

0.72

0.45

0.3

HLA-A*68-02 1028790

ic50

10

35

0.75

0.41

0.62

0.36

0.66

0.42

0.66 0.29 0.72 0.38 0.7

0.43

0.65 0.46 0.7 0.31 0.69

0.34

0.67 0.41

0.7 0.37 0.66

0.33

HLA-A*68-02 1024516

ic50

10

32

0.88

0.43

0.76

0.41

0.81

0.47

0.78 0.31 0.82 0.41 0.81

0.47

0.78 0.51 0.78 0.37 0.81

0.36

0.82 0.48 0.83 0.42 0.76

0.35

HLA-A*02-03 1028790

ic50

10

35

0.72

0.31

0.76

0.27

0.76

0.26

0.7

0.07 0.73 0.34 0.78

0.31

0.76 0.29 0.68 0.29 0.7

0.31

0.92 0.69 0.7 0.28 0.79

0.29

HLA-A*02-03 1024516

ic50

10

32

0.72

0.36

0.77

0.36

0.77

0.36

0.71 0.16 0.72 0.31 0.79

0.38

0.78 0.4 0.73 0.36 0.7

0.3

0.92 0.73 0.71 0.3

0.81

0.38

HLA-A*02-01 1028285

t1/2

11

38

0.75

0.47

0.58

0.18

0.62

0.26

0.68 0.32 0.75 0.36 0.67

0.2

0.5 0.02 0.65 0.1 0.69

0.2

0.7 0.34 0.75 0.36 0.66

0.21

29

17

8

5

14

8

10

11

Highlighed

Counts

6

2

4

3

16

9

3

2

7

4

30

30

7

5

10

4

5.2. Experimental results on Benchmark testing dataset

5.2.1
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Average AUC and SRCC

Besides counting the highest numbers of each dataset in terms of AUC and SRCC, we also
calculate the average AUC and SRCC for each algorithm based on the data in Table 5.2. As
we can see in the figure 5.2, our model and MHCFlurry both achieved the best average (0.83)
in AUC comparing with other algorithms using IEDB Benchmark Datasets. Our SRCC ranked
the second and performed a little bit less than MHCFlurry did. If only comparing within the
pan-specific algorithms, our model outperformed all the rest pan-specific models. Those results
are consistent with previous analysis by counting the highest numbers. In total, our proposed
MHCherryPan could thus be an excellent supplementary algorithm for current existing panspecific models.

Figure 5.2: Average AUC and SRCC Bar Chart

Chapter 6
Conclusion
In this chapter, We conclude the work presented in this thesis. In the end, we discuss the future
work.

6.1

Conclusion

In this thesis, we have developed MHCherryPan, a novel model combining convolutional and
recurrent neural networks for pan-specific HLA-peptide binding affinity prediction. Our model
is composed of an RNN-based peptide feature extractor, a CNN-based HLA feature extractor
and a binding predictor. The extensive benchmark experiments on HLA-I peptide binding prediction demonstrated that MHCherryPan achieved state-of-the-art performance over a majority
of the benchmark datasets from IEDB. MHCherryPan is characterized by its capability of binding prediction with only the raw amino acid sequences of HLA and peptides, which makes it
applicable to HLA-peptide binding prediction for HLA alleles without structural information.
Our main contribution is to propose a novel design combining CNN-based and RNN-based
networks inside one pan-specific model. Instead of using the consensus model to combine the
different results from various model architectures, we bring another possibility to combine the
features from different networks in one model.
56

6.2. Future Work

6.2
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Future Work

Our thesis work may be enhanced in the following. First, in this thesis, merely raw amino acid
sequence data is used for representing the input peptide and HLA protein. However, this can
be improved by including MS for the peptide. Secondly, we can further test the performance
of our MHCherryPan on alleles where few data is available. Moreover, combining our model
with current software to create a pipeline to identify neoantigens may be another meaningful
work in the future.
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Appendix A
MHCherryPan Model Summary
In the following, we provides the detailed architecture summaries for the MHCherryPan model
which we discussed in Chapter 3 and Chapter 4.
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